Physician profile
Antonio E Mancera
NPI 1750565610
$18,828.95
in general payments reported to CMS, 2019-2025
23 companies · $2,369 in 2025
The $2,369 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $181 · 2021: $14.20 · 2022: $337 · 2023: $928 · 2024: $2,097 · 2025: $2,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,258 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,258.48 |
| Education | $134.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,760.62 | 2019-2025 | |
| Celgene Corporation | $4,453.24 | 2019 | |
| Amgen INC. | $3,622.04 | 2019-2025 | Enbrel, Otezla, Otezla |
| Janssen Biotech, INC. | $1,225.54 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $902.32 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $479.42 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals Lp | $464.75 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $463.89 | 2019-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $381.97 | 2023-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $323.37 | 2019-2024 | |
| Lilly USA, LLC | $198.89 | 2019-2024 | Taltz |
| Ani Pharmaceuticals, INC. | $125.94 | 2023-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $101.37 | 2019-2023 | Actemra, Rituxan |
| Pfizer INC. | $82.55 | 2019-2024 | |
| Corcept Therapeutics | $69.29 | 2024 | Korlym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $45.17 | 2022 | |
| Arbor Pharmaceuticals, INC. | $30.67 | 2019 | |
| Orthogenrx INC. | $21.08 | 2019 | |
| Ferring Pharmaceuticals INC. | $17.84 | 2024 | Euflexxa |
| Zyla Life Sciences, INC. | $15.43 | 2019 | |
| Organon LLC | $14.99 | 2023 | Renflexis |
| Alexion Pharmaceuticals, INC. | $14.44 | 2023 | |
| Horizon Therapeutics Plc | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Mancera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.